Axsome Therapeutics (NASDAQ: AXSM) announced that the first patient has been dosed in its FOCUS-3 Phase 3 clinical trial evaluating ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE